Academic Journal

Natural killer cells: the next wave in cancer immunotherapy.

Bibliographic Details
Title: Natural killer cells: the next wave in cancer immunotherapy.
Authors: Chen X; Department of Biology, BeiGene (Beijing) Co., Ltd., Beijing, China., Jiang L; Department of Biology, BeiGene (Beijing) Co., Ltd., Beijing, China., Liu X; Department of Biology, BeiGene (Beijing) Co., Ltd., Beijing, China.
Source: Frontiers in immunology [Front Immunol] 2022 Jul 27; Vol. 13, pp. 954804. Date of Electronic Publication: 2022 Jul 27 (Print Publication: 2022).
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Language: English
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Imprint Name(s): Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms: Immunotherapy* , Neoplasms*/therapy, Immunotherapy, Adoptive ; Killer Cells, Natural ; T-Lymphocytes
Abstract: Immunotherapies focusing on rejuvenating T cell activities, like PD-1/PD-L1 and CTLA-4 blockade, have unprecedentedly revolutionized the landscape of cancer treatment. Yet a previously underexplored component of the immune system - natural killer (NK) cell, is coming to the forefront of immunotherapeutic attempts. In this review, we discuss the contributions of NK cells in the success of current immunotherapies, provide an overview of the current preclinical and clinical strategies at harnessing NK cells for cancer treatment, and highlight that NK cell-mediated therapies emerge as a major target in the next wave of cancer immunotherapy.
Competing Interests: XC is a Senior Principal Investigator at the company BeiGene (Beijing) Co., Ltd. LJ is a Senior Scientist at the company BeiGene (Beijing) Co., Ltd. XL is the Vice President, Head of Biology at the company BeiGene (Beijing) Co., Ltd.
(Copyright © 2022 Chen, Jiang and Liu.)
References: Sci Transl Med. 2019 Jul 17;11(501):. (PMID: 31316010)
J Clin Oncol. 2005 Jan 20;23(3):474-81. (PMID: 15659493)
PLoS One. 2013 Oct 18;8(10):e76781. (PMID: 24204673)
Blood. 2020 Feb 6;135(6):399-410. (PMID: 31856277)
N Engl J Med. 2022 Jan 6;386(1):24-34. (PMID: 34986285)
Cancer Cell. 2017 May 8;31(5):711-723.e4. (PMID: 28486109)
Hum Immunol. 2012 Mar;73(3):248-57. (PMID: 22234167)
Lancet. 2000 Nov 25;356(9244):1795-9. (PMID: 11117911)
Front Oncol. 2021 Apr 16;11:562315. (PMID: 33937012)
Int Immunopharmacol. 2015 Dec;29(2):635-641. (PMID: 26428847)
PLoS One. 2011;6(6):e20740. (PMID: 21698239)
Cancer Res Treat. 2021 Dec 03;:. (PMID: 34856706)
Front Immunol. 2022 Feb 22;13:828319. (PMID: 35273608)
J Clin Invest. 2018 Oct 1;128(10):4654-4668. (PMID: 30198904)
Cytotherapy. 2017 Oct;19(10):1225-1232. (PMID: 28864289)
Nat Med. 2018 Aug;24(8):1178-1191. (PMID: 29942093)
Oncotarget. 2017 Jul 12;8(51):89256-89268. (PMID: 29179517)
Haematologica. 2017 Aug;102(8):1368-1377. (PMID: 28522576)
J Transl Med. 2015 Aug 25;13:277. (PMID: 26303618)
Blood. 1997 Aug 1;90(3):1109-14. (PMID: 9242542)
Blood. 2009 Sep 24;114(13):2667-77. (PMID: 19553639)
Cancer Immunol Immunother. 2017 May;66(5):573-579. (PMID: 28197666)
Cell. 2018 Dec 13;175(7):1731-1743.e13. (PMID: 30503213)
Lancet. 2020 Sep 19;396(10254):839-852. (PMID: 32888407)
Stem Cells Transl Med. 2013 Apr;2(4):274-83. (PMID: 23515118)
Science. 2018 Dec 21;362(6421):1416-1422. (PMID: 30573629)
Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. (PMID: 28280089)
Immunol Lett. 1986 Aug;13(1-2):7-10. (PMID: 3019877)
Immunol Invest. 2015;44(6):578-89. (PMID: 26214042)
Immunol Today. 1990 Jul;11(7):237-44. (PMID: 2201309)
Front Immunol. 2020 Oct 15;11:561553. (PMID: 33178188)
Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174)
Science. 1998 Nov 6;282(5391):1145-7. (PMID: 9804556)
Nat Commun. 2016 Apr 04;7:11154. (PMID: 27040177)
Trends Immunol. 2019 Feb;40(2):142-158. (PMID: 30639050)
Blood. 2006 Jan 1;107(1):159-66. (PMID: 16150947)
Nature. 1980 Apr 10;284(5756):553-5. (PMID: 6445041)
Cancer Cell. 2016 Aug 8;30(2):324-336. (PMID: 27424807)
Science. 1980 Oct 31;210(4469):543-5. (PMID: 6158759)
Breast Cancer Res Treat. 1986;7(3):187-92. (PMID: 3779116)
Cancer Cell. 2020 Apr 13;37(4):443-455. (PMID: 32289269)
Oncotarget. 2016 Mar 29;7(13):16130-45. (PMID: 26910920)
Front Immunol. 2019 Feb 26;10:292. (PMID: 30863404)
N Engl J Med. 2021 Feb 25;384(8):705-716. (PMID: 33626253)
Clin Cancer Res. 2021 Jul 1;27(13):3744-3756. (PMID: 33986022)
PLoS One. 2017 Mar 16;12(3):e0174077. (PMID: 28301575)
Nat Immun. 1993 Jul-Oct;12(4-5):279-92. (PMID: 8257832)
Ann Pharmacother. 2022 May;56(5):609-619. (PMID: 34340597)
Br J Cancer. 1979 Jul;40(1):113-22. (PMID: 314301)
J Clin Oncol. 2022 Apr 22;:JCO2200227. (PMID: 35452273)
Haematologica. 2014 May;99(5):836-47. (PMID: 24488563)
Nature. 2014 Mar 27;507(7493):508-12. (PMID: 24553136)
Blood. 2002 Feb 1;99(3):754-8. (PMID: 11806974)
Blood Adv. 2019 Jul 9;3(13):1970-1980. (PMID: 31266741)
J Hematother Stem Cell Res. 2001 Aug;10(4):535-44. (PMID: 11522236)
Front Immunol. 2016 Mar 14;7:91. (PMID: 27014270)
Cell Rep. 2013 Aug 15;4(3):437-44. (PMID: 23933255)
Front Immunol. 2019 May 28;10:1179. (PMID: 31231370)
J Natl Cancer Inst. 1980 Nov;65(5):929-35. (PMID: 6933263)
Methods. 2014 Jan 1;65(1):18-27. (PMID: 23886909)
Nat Immunol. 2009 Jan;10(1):48-57. (PMID: 19011627)
J Clin Oncol. 2008 Apr 10;26(11):1789-96. (PMID: 18347005)
Cell Stem Cell. 2021 Dec 2;28(12):2062-2075.e5. (PMID: 34525347)
J Clin Invest. 2019 Mar 12;129(5):2094-2106. (PMID: 30860984)
Stem Cells. 2016 Jan;34(1):93-101. (PMID: 26503833)
N Engl J Med. 2020 Feb 6;382(6):545-553. (PMID: 32023374)
Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. (PMID: 30523021)
Front Immunol. 2022 Feb 03;13:841107. (PMID: 35185932)
Blood. 2002 May 15;99(10):3661-7. (PMID: 11986221)
Int J Cancer. 1982 Jul 15;30(1):107-12. (PMID: 7118294)
J Natl Cancer Inst. 1986 Oct;77(4):869-75. (PMID: 3020297)
Science. 2002 Mar 15;295(5562):2097-100. (PMID: 11896281)
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63. (PMID: 19815499)
Haematologica. 2014 Oct;99(10):1538-46. (PMID: 25271313)
Oncoimmunology. 2017 Mar 24;6(12):e1307491. (PMID: 29209559)
Blood. 2014 Jun 19;123(25):3855-63. (PMID: 24719405)
Blood. 2018 Apr 19;131(16):1809-1819. (PMID: 29449276)
Blood. 1996 Sep 15;88(6):2279-87. (PMID: 8822949)
Blood. 2012 Jun 14;119(24):5640-9. (PMID: 22535666)
Clin Cancer Res. 2011 Oct 1;17(19):6287-97. (PMID: 21844012)
J Transl Med. 2012 Nov 21;10:232. (PMID: 23171437)
Adv Immunol. 1989;47:187-376. (PMID: 2683611)
Cancer Immunol Res. 2018 Apr;6(4):458-466. (PMID: 29386186)
Molecules. 2021 Sep 27;26(19):. (PMID: 34641391)
Nat Immunol. 2018 Jul;19(7):723-732. (PMID: 29915296)
Cancer Immunol Immunother. 2020 Aug;69(8):1505-1517. (PMID: 32296919)
MAbs. 2021 Jan-Dec;13(1):1950264. (PMID: 34325617)
MAbs. 2014 May-Jun;6(3):728-39. (PMID: 24670809)
Haematologica. 2014 Jun;99(6):e81-3. (PMID: 24658821)
Nat Immunol. 2016 Jul;17(7):816-24. (PMID: 27213690)
N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490)
Front Immunol. 2017 May 29;8:573. (PMID: 28611767)
Leukemia. 1994 Apr;8(4):652-8. (PMID: 8152260)
J Biol Chem. 2003 Jan 31;278(5):3466-73. (PMID: 12427744)
J Clin Oncol. 2010 Feb 20;28(6):955-9. (PMID: 20085940)
Clin Cancer Res. 2016 Nov 1;22(21):5211-5222. (PMID: 27307594)
Nat Rev Immunol. 2018 Nov;18(11):671-688. (PMID: 30209347)
N Engl J Med. 2022 Feb 17;386(7):640-654. (PMID: 34891224)
MAbs. 2018 Jul;10(5):693-711. (PMID: 29733746)
JAMA Oncol. 2021 Apr 01;7(4):573-584. (PMID: 33480963)
Front Immunol. 2020 Sep 03;11:2156. (PMID: 33013909)
Nat Rev Immunol. 2020 Oct;20(10):633-643. (PMID: 32782358)
Nat Rev Immunol. 2007 Sep;7(9):703-14. (PMID: 17717540)
Curr Top Microbiol Immunol. 2014;382:373-92. (PMID: 25116109)
Sci Transl Med. 2016 Sep 21;8(357):357ra123. (PMID: 27655849)
Sci Immunol. 2020 Mar 20;5(45):. (PMID: 32198222)
Stem Cell Reports. 2017 Dec 12;9(6):1796-1812. (PMID: 29173894)
Cell. 2018 Dec 13;175(7):1744-1755.e15. (PMID: 30503208)
J Clin Invest. 2013 Dec;123(12):5098-103. (PMID: 24177426)
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. (PMID: 28925994)
Blood. 2020 Nov 19;136(21):2401-2409. (PMID: 32730586)
Cancer Cell. 2014 Dec 8;26(6):938. (PMID: 28898680)
Oncoimmunology. 2018 Oct 31;8(2):e1537581. (PMID: 30713793)
Cancer Immunol Immunother. 2016 Apr;65(4):485-92. (PMID: 26559813)
Blood. 2011 Sep 22;118(12):3347-9. (PMID: 21768303)
Blood. 2005 Apr 15;105(8):3051-7. (PMID: 15632206)
Cell. 2019 Jun 13;177(7):1701-1713.e16. (PMID: 31155232)
Protein Cell. 2018 Jan;9(1):63-73. (PMID: 28986820)
Immunity. 2016 Apr 19;44(4):924-38. (PMID: 27096321)
JAMA Oncol. 2017 Mar 01;3(3):335-341. (PMID: 27812689)
J Biol Chem. 2002 Jul 26;277(30):26733-40. (PMID: 11986321)
J Transl Med. 2013 May 01;11:108. (PMID: 23634660)
BMC Cancer. 2010 Jun 30;10:340. (PMID: 20591136)
Mol Cancer Ther. 2021 Jan;20(1):121-131. (PMID: 33277440)
Cancer Immunol Res. 2014 May;2(5):410-22. (PMID: 24795354)
Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6. (PMID: 32531207)
N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
Cell Stem Cell. 2018 Aug 02;23(2):181-192.e5. (PMID: 30082067)
J Hematol Oncol. 2018 Dec 20;11(1):141. (PMID: 30572922)
Immunol Cell Biol. 2020 Apr;98(4):287-304. (PMID: 32157732)
Eur J Immunol. 2015 Oct;45(10):2886-97. (PMID: 26171588)
Cancer Immunol Res. 2018 Dec;6(12):1548-1560. (PMID: 30282672)
Sci Transl Med. 2020 Nov 4;12(568):. (PMID: 33148626)
Cancer Immunol Res. 2019 Apr;7(4):644-657. (PMID: 30745366)
Cell. 2018 Feb 22;172(5):1022-1037.e14. (PMID: 29429633)
Annu Rev Immunol. 2013;31:227-58. (PMID: 23516982)
Contributed Indexing: Keywords: NK cell therapy; cancer; iPSC-NK; immune checkpoint; immunotherapy; natural killer (NK) cells
Entry Date(s): Date Created: 20220815 Date Completed: 20220816 Latest Revision: 20220825
Update Code: 20221216
PubMed Central ID: PMC9364606
DOI: 10.3389/fimmu.2022.954804
PMID: 35967421
Database: MEDLINE
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2022.954804